Unknown PHASE3 INTERVENTIONAL NCT00000146

Optic Neuritis Treatment Trial (ONTT)

Sponsor: National Eye Institute (NEI)

Conditions Multiple Sclerosis Optic Neuritis

Interventions Methylprednisolone Prednisone

Updated 6 times since 2017 Last updated: Jun 2, 2006 Started: Jul 31, 1988

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00000146, this PHASE3 trial focuses on Multiple Sclerosis and Optic Neuritis and remains ongoing. Sponsored by National Eye Institute (NEI), it has been updated 6 times since 1988, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE3
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE3
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE3

First recorded

Jul 1988

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Eye Institute (NEI)

Data source: National Eye Institute (NEI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Baltimore, United States , Chicago, United States , Durham, United States , East Lansing, United States , Gainesville, United States , Houston, United States , Iowa City, United States , Little Rock, United States , New York, United States and 5 more locations